N-substituted derivatives of 3r, 4r-ethyl- ((1-methyl-1h-imidazol-5-yl)methyl)-2-pyrrolidinone
CA 2027604 A1 · Owner: Allergan, Inc. · Inventors: Albaugh, Pamela
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
ALLGN.02A PATENT, ABSTRACT OF DISCLOSURE The present invention relates to new carbonyl 3R,4Rethyl-(1-methyl-1H-imidazol-5-yl)methyl-2-pyrrolidinone derivatives carrying a carboxyester-type lipophilic moiety on the pyrrolidinone nitrogen. More particularly the, present invention concerns new N-substituted carbonyl- 3R,4R-ethyl-(1-methyl-1H-imidazol-5-yl)methyl-2pyrrolidinone derivatives of the formula (I): wherein R is an optionally substituted hydrocarbon group and pharmaceutically acceptable acid addition salts thereof. The new compounds of the formula (I) are potent ocular hypotensives that are valuable antiglaucoma agents. They are also targeted for use in the treatment of so-called dry …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 15, 1990. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 15, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 15, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.